Fierce Pharma Asia—China's IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe's dermatology deal

China's investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of transparency.

| China's investigator-initiated trials, once praised for their .